10-K Decoder · All companies

AN2 Therapeutics, Inc.

ANTX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$0K$0K
Operating income−$38.1M−$56.8M+32.9%
Net income−$35.2M−$51.3M+31.5%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026

$Q3 2026Year earlierChange
Revenue$0K$0K
Operating income−$8.70M−$10.0M+13.0%
Net income−$8.00M−$9.40M+14.9%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was AN2 Therapeutics's revenue in FY2025?
$0K in FY2025 (Fiscal year ended Dec 31, 2025), no comparable figure vs $0K a year earlier, per its 10-K filed Mar 2026.
Was AN2 Therapeutics profitable in FY2025?
No: net income was −$35.2M and operating income −$38.1M in FY2025.
What was AN2 Therapeutics's revenue in Q3 2026?
$0K (n/a vs a year earlier), per its Form 10-Q filed Nov 9, 2026.